SCHEMBL23930514

SCHEMBL23930514

CC(C(N)=O)N(c1ccc(F)cc1)c1nc(N)c(C(=O)c2cc(C3CCCC3)no2)s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 1/20 0.35
PSMB9 P28065 1/20 0.35
PSMB5 P28074 1/20 0.35
MAPT P10636 4/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
POLB P06746 1/20 0.34
CDK5 Q00535 4/20 0.33
CDK5R1 Q15078 4/20 0.33
TP53 P04637 2/20 0.33
NPC1 O15118 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
LMNA P02545 2/20 0.31
KDM4E B2RXH2 2/20 0.30
HPGD P15428 2/20 0.30
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30
CASP1 P29466 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30210952 1.00 PSMB8 (0.35) PSMB8PSMB9PSMB5MAPTKMT2A
SCHEMBL23930603 0.85 NPC1 (0.46) KMT2AMEN1TP53NPC1HPGD
SCHEMBL30210831 0.85 NPC1 (0.46) KMT2AMEN1TP53NPC1HPGD
SCHEMBL23930496 0.85 MAPT (0.37) MAPTKMT2AMEN1POLBCDK5
SCHEMBL30437290 0.85 MAPT (0.37) MAPTKMT2AMEN1POLBCDK5
SCHEMBL23930510 0.85 KMT2A (0.33) MAPTKMT2AMEN1POLBCDK5
SCHEMBL30210942 0.85 CDK5 (0.33) MAPTKMT2AMEN1POLBCDK5
SCHEMBL30210775 0.85 KMT2A (0.33) MAPTKMT2AMEN1POLBCDK5
SCHEMBL30210861 0.85 MAPT (0.33) MAPTKMT2AMEN1POLBCDK5
SCHEMBL23930467 0.84 MAPT (0.35) MAPTKMT2AMEN1POLBCDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP claimed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US claimed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 EP claimed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 CN claimed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 WO claimed
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG PSMB8 2758/4885PSMB9 1723/4885PSMB5 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.